Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the hypothalamic signal that instructs the pituitary gland to release growth hormone. What makes it distinctive in the research literature is its logic: rather than delivering growth hormone directly, tesamorelin works one step upstream, prompting the body to secrete its own growth hormone in a natural, pulsatile rhythm. It is also one of the relatively few research peptides that has passed through large controlled human trials and reached a formal regulatory approval.
This guide summarizes what the peer-reviewed literature and regulatory record report about tesamorelin — its mechanism, its effects on the GH/IGF-1 axis and visceral fat, and, just as importantly, the boundaries of what is actually established.
Most approaches to raising growth hormone (GH) involve injecting recombinant GH itself. Tesamorelin takes the opposite route. As a stabilized GHRH analog, it binds GHRH receptors on the anterior pituitary and increases the pulsatile secretion of endogenous GH. The word "pulsatile" matters: the body's own GH is released in bursts, and preserving that pattern — rather than flooding the system with a constant exogenous supply — is a central reason researchers study GHRH analogs as a more physiological tool for probing the GH axis.
Native GHRH is broken down very quickly in the bloodstream. Tesamorelin is a modified GHRH(1–44) peptide engineered for greater metabolic stability, which allows it to reach the pituitary and act as a functional secretagogue in experimental settings.
When GH secretion rises, the liver and peripheral tissues respond by producing more insulin-like growth factor 1 (IGF-1). IGF-1 is the mediator through which much of GH's activity is expressed, and it is also the most convenient blood marker for confirming that a GHRH analog is doing something. In controlled research, tesamorelin has been shown to elevate IGF-1 substantially while, in the studied populations, keeping levels within the normal range for age rather than pushing them to supraphysiological extremes. This "restore the signal within physiological bounds" behavior is a recurring theme in the tesamorelin literature and part of why it became a reference GHRH analog.
The observation that made tesamorelin genuinely notable concerns visceral adipose tissue (VAT) — the metabolically active fat packed deep in the abdomen around the organs, which is distinct from subcutaneous fat and more strongly linked to metabolic risk. Across randomized, placebo-controlled trials, tesamorelin has been associated with a selective reduction of visceral fat, with comparatively little effect on subcutaneous fat.
In HIV-infected patients with abdominal fat accumulation, a randomized clinical trial reported by Stanley and colleagues in JAMA (2014) found that tesamorelin significantly reduced visceral fat and also lowered liver fat over six months versus placebo. In a separate randomized study of obese subjects with reduced GH secretion, Makimura and colleagues reported a meaningful net reduction in VAT alongside an approximately 90% increase in IGF-1 relative to placebo. The consistent pattern — GH/IGF-1 elevation coupled with preferential loss of visceral fat — is what anchors tesamorelin's place in metabolic and body-composition research.
Unlike most compounds in the research-peptide space, tesamorelin corresponds to an FDA-approved pharmaceutical. Under the brand name Egrifta (and later formulations such as Egrifta SV), tesamorelin for injection carries a U.S. approved indication for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, with an initial U.S. approval in 2010. The FDA prescribing information describes its mechanism as a growth-hormone-releasing factor analog that increases GH and, consequently, IGF-1.
Two things must be stated clearly. First, that approval is narrow and specific: it addresses an HIV-related condition under medical supervision, and the label carries important limitations, warnings and monitoring requirements that are outside the scope of this research-oriented page. Second, and critically, the existence of an approved drug product does not make research-grade tesamorelin a medicine. The approval attaches to a specific, regulated, finished drug product — not to laboratory reference material. Nothing here is a treatment claim, a weight-loss claim, or a suggestion that anyone use tesamorelin.
Tesamorelin sits on firmer ground than many research peptides: its GHRH-analog mechanism is well characterized, and its effect on the GH/IGF-1 axis and visceral fat has been demonstrated in randomized, controlled human trials. That is a genuinely substantial body of evidence.
At the same time, the well-established human data are concentrated in the specific studied populations — most prominently HIV-associated lipodystrophy. Extrapolating those results to other groups, other endpoints (such as general body composition, longevity or cognition), or long-term outcomes goes beyond what the controlled evidence supports. As with any agent that acts on the GH axis, questions around glucose metabolism, IGF-1 exposure and durability of effect are matters of ongoing investigation. Treating a narrow, well-proven indication as a broad guarantee is exactly the error this field is prone to, and we won't make it here.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The Tesamorelin we supply to the research community is a lyophilized powder with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH). In research it is studied as a secretagogue that stimulates the pituitary to release the body's own growth hormone in a pulsatile pattern, rather than supplying growth hormone directly.
Tesamorelin binds GHRH receptors on the pituitary and increases pulsatile secretion of endogenous growth hormone (GH), which in turn raises circulating insulin-like growth factor 1 (IGF-1). In clinical research this GH/IGF-1 signaling has been associated with selective reduction of visceral adipose tissue.
Yes. As a finished pharmaceutical drug product under the brand name Egrifta, tesamorelin has an FDA-approved indication for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, first approved in the United States in 2010. That approval applies to the specific prescription drug product, not to research-grade material.
No. The Tesamorelin supplied by Universe Peptide is a research compound intended strictly for in-vitro laboratory use. It is not the FDA-approved drug product Egrifta, is not a medicine, and is not for human or animal consumption.